This announcement summarizes Bioretec Ltd's business review for January-March 2026. The complete business review is attached to this release as a PDF file and available on the company's website at https://investors.bioretec.com/en/reports_and_presentations.
January–March 2026 in brief
Net sales amounted to EUR 1,220 thousand (1–3/2025: EUR 1,396 thousand)
Adjusted sales margin was 70.1% (56.7%) of net sales. From Q1/2026, the company will transition to reporting adjusted sales margin to be aligned with industry reporting standards. Adjusted sales margin comprises the net sales of implants deducted by related cost of sales and extraordinary expenses.
EBITDA was EUR -1,375 (-1,236) thousand
The result for the reporting period amounted to EUR -1,371 (-1,298) thousand
On March 27, Bioretec announced that the Board of Directors has resolved on a rights issue
The rights issue was completed after the end of the reporting period. The final results of the rights issue show that a total of 1,286,801,534 new shares were subscribed for in the offering, corresponding to approximately 87.1 per cent of the 1,477,828,416 new shares offered in the offering. The subscription price in the offering was EUR 0.01 per new share. Bioretec receives gross proceeds of approximately EUR 12.9 million from the offering.
Key figures
EUR 1,000 unless otherwise indicated
1–3/2026
1–3/2025
Change, %
1–12/2025
Net sales
1,220
1,396
-12.6 %
3,522
Adjusted sales margin, % of net sales 1
70.1 %
56.7 %
59.3 %
EBITDA
-1,375
-1,236
-8,476
EBIT
-1,435
-1,287
-8,686
Profit / loss for the period
-1,371
-1,298
-9,483
R&D expenditure, % of net sales
47.3 %
45.7 %
85.8 %
Equity ratio, %
82.2 %
82.2 %
84.3 %
Cash and cash equivalents
1,880
4,424
-57.5 %
4,126
Earnings per share (undiluted)
-0.04
-0.06
-0.34
Earnings per share (diluted)
-0.04
-0.05
-0.28
Number of shares
30,788,092
23,336,858
